These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 30920172)

  • 1. Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.
    Xu H; Yang G; Yang L; Yang Y; Ma D; Li J; Hao X; Xing P; Wang Y
    Thorac Cancer; 2019 May; 10(5):1096-1102. PubMed ID: 30920172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
    Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
    Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.
    Ma D; Zhang Y; Xing P; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang H; Du Y; Zhang Z; Liang L; Li J
    Thorac Cancer; 2019 May; 10(5):1213-1219. PubMed ID: 30993895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
    Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
    Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
    Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
    Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
    Wu L; Zou Z; Li Y; Hao X; Ying J; Li J; Xing P
    J Transl Med; 2024 Jun; 22(1):585. PubMed ID: 38902768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
    Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
    Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
    Soria JC; Ho SN; Varella-Garcia M; Iafrate AJ; Solomon BJ; Shaw AT; Blackhall F; Mok TS; Wu YL; Pestova K; Wilner KD; Polli A; Paolini J; Lanzalone S; Green S; Camidge DR
    Ann Oncol; 2018 Sep; 29(9):1964-1971. PubMed ID: 30010763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
    Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
    Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
    Ou SH; Jänne PA; Bartlett CH; Tang Y; Kim DW; Otterson GA; Crinò L; Selaru P; Cohen DP; Clark JW; Riely GJ
    Ann Oncol; 2014 Feb; 25(2):415-22. PubMed ID: 24478318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
    Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L
    J Thorac Oncol; 2024 Jun; 19(6):912-927. PubMed ID: 38280448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer.
    Deng H; Li B; Li L; Peng J; Lv T; Liu Y; Ding C
    Pathol Res Pract; 2019 Dec; 215(12):152695. PubMed ID: 31699471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
    Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
    Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.
    Yang G; Ma D; Xu H; Yang L; Li J; Xing P; Hao X; Wang Y
    Cancer Med; 2019 Oct; 8(13):5823-5830. PubMed ID: 31407528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.